Global Fibrinogen Concentrates Market – Dynamics
Several launches and approvals of new fibrinogen concentrates are expected to boost growth of the fibrinogen concentrates market over the forecast period. For instance, in March 2017, LFB Biopharmaceuticals launched FibCLOT, a human fibrinogen concentrate. FibCLOT is used for the patients with congenital hypo-fibrinogenaemia or afibrinogenaemia.
Furthermore, increasing number of market players are focusing on developing fibrinogen concentrates to treat the bleeding incidences in patients with congenital fibrinogenemia, in order to, which is also contributing to the market growth over the forecast period. For instance, in March 2013, Biotest AG initiated a phase 3 clinical study for investigating the safety and efficacy of fibrinogen concentrate from human plasma for the treatment of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia. The study is expected to complete in November 2020.
Fibrinogen Concentrates Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients